Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2000
10/24/2000US6136858 Mixture of vegetable oils
10/24/2000US6136845 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl PCDFs
10/24/2000US6136839 Using a sulfone or sulfoamide benzene compound
10/24/2000US6136835 Methods of treatment for viral infections
10/24/2000US6136812 Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
10/24/2000US6136804 Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
10/24/2000US6136796 Drugs for antiischemic agents, strokes, antiepileptic agents and antiasthma agents
10/24/2000US6136795 Antiarthritic agents by administering linolenic acid and omega 3 fatty acids
10/24/2000US6136794 Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
10/24/2000US6136780 Administering naltrexone or naloxone to treat gastrointestinal cancer, particularly colon or pancreatic cancer
10/24/2000US6136602 Nucleotide sequences which can hybridize to preferential target nucleic acids; for the suppression of the expression of genes associated with antibiotic resistance and the prevention of bacterial infections
10/24/2000US6136596 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
10/24/2000US6136556 TCTS response regulator
10/24/2000US6136532 Methods for treating bipolar mood disorder associated with markers on chromosome 18q
10/24/2000US6136367 Composition and its use as a food supplement or for lowering lipids in serum
10/24/2000US6136344 Oral pharmaceutical dosage form
10/24/2000US6136337 Comprises an acrylic acid polymer, a vasoconstrictor, and a rectal tissue-curing agent; suppository; for curing hemorrhoids or the like
10/24/2000US6136332 Dermatological/pharmaceutical compositions comprising volatile oils/phenylated silicone oils
10/24/2000US6136317 Chromium picolinate compositions
10/24/2000CA2220873C Method for reproducing in vitro the rna-dependent rna polymerase and terminal nucleotidyl transferase activities encoded by hepatitis c virus (hcv)
10/19/2000WO2000062068A1 Method to type prion proteins
10/19/2000WO2000062067A1 Novel transduction molecules and methods for using same
10/19/2000WO2000061793A2 Novel method for identifying antibacterial compounds
10/19/2000WO2000061792A1 Novel essential bacterial genes and their proteins
10/19/2000WO2000061779A1 49 human secreted proteins
10/19/2000WO2000061757A1 Tumor necrosis factor homologs and nucleic acids encoding the same
10/19/2000WO2000061751A1 REAGENTS AND METHODS FOR IDENTIFYING AND MODULATING EXPRESSION OF GENES REGULATED BY p21
10/19/2000WO2000061750A2 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS
10/19/2000WO2000061746A1 13 transmembrane protein expressed in prostate cancer
10/19/2000WO2000061637A1 Erythropoietin receptor antibodies
10/19/2000WO2000061606A1 Novel human voltage-gated potassium channel
10/19/2000WO2000061597A1 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
10/19/2000WO2000061590A1 Process for preparing amine platinum complexes
10/19/2000WO2000061568A2 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
10/19/2000WO2000061551A2 Pyrimidine-2-one derivatives as integrin receptor ligands
10/19/2000WO2000061543A2 Esters of l-carnitine or alkanoyl l-carnitines
10/19/2000WO2000061234A1 Combinations of gaba analogs and tricyclic compounds to treat depression
10/19/2000WO2000061231A2 Medical use
10/19/2000WO2000061230A2 Estrogen receptors-beta antagonism and bone diseases
10/19/2000WO2000061188A1 Sodium channel blocker compositions and the use thereof
10/19/2000WO2000061182A2 Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist
10/19/2000WO2000061180A2 Products and methods for treating ptp lar related diseases
10/19/2000WO2000061171A2 Uses of mammalian ox2 protein and related reagents
10/19/2000WO2000061167A2 TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
10/19/2000WO2000061164A1 Modulation of excitable tissue function by peripherally administered erythropoietin
10/19/2000WO2000061152A1 Management of pain after joint surgery
10/19/2000WO2000061151A2 Oligodeoxynucleotide and its use to induce an immune response
10/19/2000WO2000061145A1 Methods of inducing cancer cell death and tumor regression
10/19/2000WO2000061142A1 Method and composition for the treatment of cancer
10/19/2000WO2000061132A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
10/19/2000WO2000061126A2 Method of treating neurological disorders with combinations of nitric oxide synthase inhibitors and excitatory amino acid receptor modulators
10/19/2000WO2000061110A1 Icecream-type pharmaceutical formulation and process for preparing the same
10/19/2000WO2000061106A1 Antimicrobial wipes which provide improved immediate germ reduction
10/19/2000WO2000061078A2 Sunscreen agents containing hydroxycarboxylic acid alkyl- and/or -alkenyloligoglycoside esters
10/19/2000WO2000061068A2 Anthelmintic compositions
10/19/2000WO2000060953A2 Methods for stabilizing liquid nutritional products and products so stabilized
10/19/2000WO2000060943A1 Prevention of brain damage in stroke
10/19/2000WO2000060939A1 Lubrication composition
10/19/2000WO2000060932A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1
10/19/2000WO2000041505A3 Anthranilic acid derivatives
10/19/2000WO2000038620A3 A composition useful to treat periodontal disease
10/19/2000WO2000035484A3 Methods and compositions for decreasing allergic reactions to surface allergens
10/19/2000WO2000035420A3 Stable surgical irrigating solutions
10/19/2000WO2000034780A3 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?
10/19/2000WO2000032778A3 Methods and compositions for inhibiting neoplastic cell growth
10/19/2000WO2000024437A3 Textured and porous silicone rubber
10/19/2000WO2000019883A9 Compositions and methods of disease diagnosis and therapy
10/19/2000WO2000013702A9 Use of an angiogenic factor for the treatment of microvascular angiopathies
10/19/2000WO2000009070A3 Inhibition of pathogenic processes related to tissue trauma
10/19/2000DE19916208A1 Sonnenschutzmittel Sunscreens
10/19/2000DE19915465A1 Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten Using a Caspase inhibitor for the inhibition of proliferation of cells and using one or more caspase inhibitor / s for the treatment of diseases based on lymphocyte hyperproliferation or for suppression of an immune response by lymphocytes
10/19/2000CA2383940A1 Modulation of excitable tissue function by peripherally administered erythropoietin
10/19/2000CA2382628A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
10/19/2000CA2370000A1 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
10/19/2000CA2369822A1 Novel human voltage-gated potassium channel
10/19/2000CA2369629A1 Method to type prion proteins
10/19/2000CA2369454A1 Uses of mammalian ox2 protein and related reagents
10/19/2000CA2369420A1 Treatment of myeloma bone disease with proteasomal and nf-kb activity inhibitors
10/19/2000CA2369413A1 Transmembrane protein expressed in prostate and other cancers
10/19/2000CA2369303A1 Method and composition for the treatment of cancer
10/19/2000CA2369301A1 Management of pain after joint surgery
10/19/2000CA2369156A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1
10/19/2000CA2368937A1 Prevention of brain damage in stroke
10/19/2000CA2368648A1 Estrogen receptors and bone
10/19/2000CA2368049A1 Integrin receptor ligands
10/19/2000CA2367494A1 Combinations of gaba analogs and tricyclic compounds to treat depression
10/19/2000CA2366359A1 Novel essential bacterial genes and their proteins
10/19/2000CA2365945A1 Products and methods for treating ptp lar related diseases
10/19/2000CA2365929A1 Novel method for identifying antibacterial compounds
10/19/2000CA2365918A1 49 human secreted proteins
10/19/2000CA2365913A1 Tumor necrosis factor receptor homologs and nucleic acids encoding the same
10/19/2000CA2365908A1 Reagents and methods for identifying and modulating expression of genes regulated by p21
10/19/2000CA2365623A1 Tyrosine kinase substrate (tks) proteins
10/19/2000CA2364690A1 Novel transduction molecules and methods for using same
10/19/2000CA2364675A1 Methods of inducing cancer cell death and tumor regression
10/18/2000EP1044689A1 Solid iodophor preparations and process for producing the same
10/18/2000EP1044277A2 Recombinant, active caspases and uses thereof
10/18/2000EP1044266A2 Human signal peptide-containing proteins
10/18/2000EP1044197A2 New piperidinyl-substituted pyridylalkane, alkene and alkine carboxamides
10/18/2000EP1044023A1 A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia
1 ... 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 ... 1151